Fig. 1From: Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejectionRenal allograft survival censoring death after c-aABMR diagnose. Treatment: patients under rituximab-containing treatment (yes), control patient group (no). Chronic active antibody-mediated rejection (c-aABMR)Back to article page